Sativex Review: Effective Across Multiple Pain Conditions Without Tolerance or Withdrawal | Research

The takeaway

Clinical assessment of Sativex (THC:CBD spray) demonstrated efficacy across intractable neuropathic pain, brachial plexus injury pain, advanced cancer pain, rheumatoid arthritis, and MS symptoms, without significant intoxication, tolerance, or withdrawal syndrome.

Read this if you want a broad overview of what clinical trials have shown about the THC:CBD spray Sativex across different conditions.

No significant intoxication, tolerance, or withdrawal syndrome reported across Sativex clinical trials

What the researchers found

This review covered the clinical development of Sativex as a combined cannabinoid medicine (THC and CBD) delivered via oromucosal spray. The spray delivery system was designed to maintain therapeutic levels while minimizing psychoactive effects.

Sativex had been shown to be well tolerated and successfully self-administered and self-titrated in both healthy volunteers and patient cohorts. Clinical trials demonstrated efficacy across a range of conditions: intractable chronic neuropathic pain, brachial plexus nerve injury pain, allodynic peripheral neuropathic pain, advanced cancer pain, rheumatoid arthritis, and MS symptoms (bladder problems, spasticity, central pain).

Notably, trials reported no significant intoxication-like symptoms, no development of tolerance, and no withdrawal syndrome upon discontinuation.

Why it matters

The absence of tolerance, withdrawal, and significant intoxication addressed three major concerns about cannabis-based medicines. If patients can use a cannabinoid medicine long-term without needing escalating doses or experiencing withdrawal when stopping, it makes the treatment more practical and reduces concerns about dependence.

The numbers in context

Conditions with demonstrated efficacy: intractable neuropathic pain, brachial plexus injury pain, allodynic neuropathic pain, advanced cancer pain, rheumatoid arthritis, MS bladder problems, MS spasticity, MS central pain. No significant intoxication, tolerance, or withdrawal reported.

How the study worked

Clinical review of Sativex development program covering pharmacology, delivery system, healthy volunteer studies, and clinical trials across multiple pain and neurological conditions.

What this study cannot tell us

This review was written from a perspective favorable to the product. Individual trials for some conditions had small sample sizes. The absence of tolerance and withdrawal may partly reflect the relatively short duration of most trials. The optimistic framing may not capture all safety concerns.

How to read the evidence

Clinical review of multiple trials. Provides a useful overview but some individual trials had small samples, and the favorable perspective may not capture all safety nuances.

When this study was published

Published in 2006. Sativex has since accumulated extensive real-world use data across 25+ countries, generally supporting these efficacy and safety findings.

The bigger picture

The combination of THC and CBD in Sativex was intentional: CBD may mitigate some of THC's psychoactive effects while contributing its own therapeutic properties. The broad range of pain conditions showing benefit positions Sativex as a versatile analgesic option.

Questions still open

Does the absence of tolerance persist with very long-term use? How does Sativex compare head-to-head with established analgesics for each condition? Does the THC:CBD ratio explain the apparent absence of significant intoxication?

Common questions

Does Sativex cause a high?

Clinical trials reported no significant intoxication-like symptoms with Sativex. The combination of THC with CBD, and the self-titrating spray delivery, appear to minimize psychoactive effects while maintaining therapeutic benefit.

Does Sativex cause dependence or withdrawal?

No withdrawal syndrome or development of tolerance was reported in the clinical trials reviewed. However, most trials were of relatively short duration, and very long-term effects may differ.

Read the original research

Combined cannabinoid therapy via an oromucosal spray.

Drugs of today (Barcelona, Spain : 1998), 42(8), 495-503

View on PubMed ↗

Citation

Perez, Jordi. (2006). Combined cannabinoid therapy via an oromucosal spray.. Drugs of today (Barcelona, Spain : 1998), 42(8), 495-503.